ReviewTheScientificWorldJournal2014
Interpatient variability in dexmedetomidine response: a survey of the literature.
Review in TheScientificWorldJournal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 49 citations in OpenAlex.
- A systematic review of dexmedetomidine pharmacology in pediatric patients.Clinical and translational science · 2024Pooled it
- Pooled it
- Comparison of three sedation regimens for drug-induced sleep endoscopy.Sleep & breathing = Schlaf & Atmung · 2015Trial
- Dexmedetomidine and Chloral Hydrate Sedation on ABR Indices in Children.Audiology research · 2026Article
- Dexmedetomidine: Shifting Paradigms in Neonatal Sedation and Pain Control.Children (Basel, Switzerland) · 2025Review
- Response to "Comment on Effects of remimazolam versus dexmedetomidine on recovery after transcatheter aortic valve replacement under monitored anesthesia care: a propensity score-matched, non-inferiority study".Korean journal of anesthesiology · 2025Article
- Clinical Effects and Pharmacokinetic Profile of Intramuscular Dexmedetomidine (10 μg/kg) in Cats.Animals : an open access journal from MDPI · 2024Article
- Pharmacogenetic and pharmacokinetic factors for dexmedetomidine-associated hemodynamic instability in pediatric patients.Frontiers in pharmacology · 2024Article
- EEG response of dexmedetomidine during drug induced sleep endoscopy.Frontiers in neuroscience · 2023Article
- Genetic polymorphisms are associated with individual susceptibility to dexmedetomidine.Frontiers in genetics · 2023Article
- Circulating microRNA-30a-5p, microRNA-101-3p, microRNA-140-3p and microRNA-141-3p as potential biomarkers for dexmedetomidine response in pediatric patients.European journal of clinical pharmacology · 2021Article
- The Use of Propofol versus Dexmedetomidine for Patients Receiving Drug-Induced Sleep Endoscopy: A Meta-Analysis of Randomized Controlled Trials.Journal of clinical medicine · 2021Review
- Pharmacokinetics of Dexmedetomidine in Infants and Children After Orthotopic Liver Transplantation.Anesthesia and analgesia · 2020Article
- Prevention and management of delirium in critically ill adult patients in the intensive care unit: a review based on the 2018 PADIS guidelines.Acute and critical care · 2019Review
- Liquid Biopsies in Lung Cancer: Four Emerging Technologies and Potential Clinical Applications.Cancers · 2019Article
- Recovery time after oral and maxillofacial ambulatory surgery with dexmedetomidine: an observational study.Clinical oral investigations · 2019Observational
- Pharmacogenomics of Medications Commonly Used in the Intensive Care Unit.Frontiers in pharmacology · 2018Review
- The pharmacogenomics of severe traumatic brain injury.Pharmacogenomics · 2017Review
- Clinical Pharmacokinetics and Pharmacodynamics of Dexmedetomidine.Clinical pharmacokinetics · 2017Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Fifty-five thousand patients are cared for in the intensive care unit (ICU) daily with sedation utilized to reduce anxiety and agitation while optimizing comfort. The Society of Critical Care Medicine (SCCM) released updated guidelines for management of pain, agitation, and delirium in the ICU and recommended nonbenzodiazepines, such as dexmedetomidine and propofol, as first line sedation agents. Dexmedetomidine, an alpha-2 agonist, offers many benefits yet its use is mired by the inability to consistently achieve sedation goals. Three hypotheses including patient traits/characteristics, pharmacokinetics in critically ill patients, and clinically relevant genetic polymorphisms that could affect dexmedetomidine response are presented. Studies in patient traits have yielded conflicting results regarding the role of race yet suggest that dexmedetomidine may produce more consistent results in less critically ill patients and with home antidepressant use. Pharmacokinetics of critically ill patients are reported as similar to healthy individuals yet wide, unexplained interpatient variability in dexmedetomidine serum levels exist. Genetic polymorphisms in both metabolism and receptor response have been evaluated in few studies, and the results remain inconclusive. To fully understand the role of dexmedetomidine, it is vital to further evaluate what prompts such marked interpatient variability in critically ill patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.